A
André Bosly
Researcher at Université catholique de Louvain
Publications - 212
Citations - 13388
André Bosly is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Diffuse large B-cell lymphoma & International Prognostic Index. The author has an hindex of 51, co-authored 209 publications receiving 12569 citations. Previous affiliations of André Bosly include Catholic University of Leuven.
Papers
More filters
Journal ArticleDOI
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
P. Feugier,A. Van Hoof,Catherine Sebban,Philippe Solal-Celigny,R. Bouabdallah,Christophe Fermé,B. Christian,Eric Lepage,H. Tilly,F. Morschhauser,Philippe Gaulard,Gilles Salles,André Bosly,Christian Gisselbrecht,Felix Reyes,B. Coiffier +15 more
TL;DR: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up.
Journal ArticleDOI
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht,Bertram Glass,Nicolas Mounier,Devinder Gill,David C. Linch,Marek Trneny,André Bosly,Nicolas Ketterer,Ofer Shpilberg,Hans Hagberg,David D.F. Ma,Josette Brière,Craig H. Moskowitz,Norbert Schmitz +13 more
TL;DR: It is found that patients with early relapses after rituximab-containing first-line therapy have a poor prognosis, with no difference between the effects of R-ICE and R-DHAP.
Journal ArticleDOI
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
Pierre W. Wijermans,Michael Lübbert,Gregor Verhoef,André Bosly,Christophe Ravoet,Marc André,Augustin Ferrant +6 more
TL;DR: It is confirmed that DAC therapy was effective in half of the studied patients with high-risk myelodysplastic syndrome and is especially active in the patients with the worst prognoses.
Journal ArticleDOI
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Nicolas Mounier,Josette Brière,Christian Gisselbrecht,Jean-François Emile,Pierre Lederlin,Catherine Sebban,Françoise Berger,André Bosly,Pierre Morel,Hervé Tilly,Reda Bouabdallah,Felix Reyes,Philippe Gaulard,Bertrand Coiffier +13 more
TL;DR: Rituximab is able to prevent chemotherapy failure in patients with bcl-2 protein overexpression, and is associated with a better overall survival and event-free survival than R-CHOP in b cl-2+ patients.
Journal ArticleDOI
Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas
Christian Gisselbrecht,Philippe Gaulard,Eric Lepage,Bertrand Coiffier,Josette Brière,Corinne Haioun,Dominique Cazals-Hatem,André Bosly,Luc Xerri,Hervé Tilly,Françoise Berger,Reda Bouhabdallah,Jacques Diebold +12 more
TL;DR: Although the poor prognosis of non-ALCL PTCL could be due in part to the presence of adverse prognostic factors at diagnosis, this study shows that the T-cell phenotype is an independent significant factor, which should be incorporated into the definition of prognostic groups.